An introduction to the report
All the information pertaining to the market of this rare form of cancer is provided in our recently published report “Malignant Mesothelioma Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” Caused due to the exposure to toxic asbestos, the occurrence of this cancer is higher in countries such as Russia and China. These two countries are pegged to represent the most lucrative markets, owing to the relatively high production of asbestos in these countries. Besides, a high consumption of asbestos in the APAC region is expected to create a sizeable opportunity for key players in this market. Our analysts have observed that the rapid substitution through generics to ease availability and affordability is the key focus area in the global malignant mesothelioma market. We have observed that the application of combination therapies is gaining traction in the market across regions. Documented evidence on the adoption of combination treatments and benefits is being made available to ease patients’ journey through the treatment process. According to our analysts, there is a great need in the market to efficiently meet the requirements for the present treatment regimen. The drugs that are currently in use do not show much response rates. The malignant mesothelioma treatment market requires drugs to increase the current survival rate.
Acquisitions and collaborations are the key strategies adopted by players to develop molecules for the better treatment of malignant mesothelioma. Companies are focusing on collaborating with established research centers and other cancer drug manufacturers to develop drugs. Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.
We have used our in-house epidemiology data based model to estimate the global malignant mesothelioma market numbers
Weighted average selling price has been considered to estimate the market size of various drugs mentioned in the scope of the study. Price per country is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard. We have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions. Prices considered in the models are standardized based on the average dosage used per malignant mesothelioma treatment per dosage cycle of six months. Availability of branded off-patent equivalents has been taken into consideration while calculating prices. We have adopted the bottom-up approach to forecast the malignant mesothelioma market globally. Besides this, forecasting is done using our internal proprietary model that considers different macro-economic factors, industry based demand driving factors impacting the market and the relevant forecast trends apart from disease related factors.
Route of Administration
Our research methodology leverages both primary and secondary research to collect the relevant market data. We have analyzed the global malignant mesothelioma market by considering key player revenue, usage patterns, historic trends, and problems faced by oncologists, the required treatment developments, and most preferred drugs. Key opinion leaders including experienced healthcare professionals in various healthcare facilities at the country level have been considered for primary research. These estimates have been further validated with drug manufacturers, distributors, and suppliers. Extensive secondary research has been carried out to understand the epidemiology of malignant mesothelioma, treatment rate, adoption rate, regulatory scenarios, average selling price and the global reimbursement scenario by referring to published scientific literature from various databases such as the WHO, Asbestos.com, PubMed, Springer, and Wiley among many others. We have also analyzed the various companies’ annual reports, investor presentations, SEC filings, reports and press releases to fetch substantial information pertaining to the market size, trends, opportunities, drivers, and restraints.
Pemetrexed and combination segment anticipated to grab half the market share of the global malignant mesothelioma market
Pemetrexed and combination segment is the largest segment by drug type in the global malignant mesothelioma market, which is estimated to represent close to US$ 160 Mn, or more than 45% revenue share of the total market in 2017 and more than US$ 300 Mn by the end of the forecast period of 2017–2025, expanding at CAGR of 8.4%. Pemetrexed and combination segment is expected to gain more than 300 BPS in market share in 2025 over 2017 owing to its better response rate of around 30%-40% when used singly or in combination with other drugs. Pemetrexed and combination drug type segment dominated the global malignant mesothelioma market in terms of revenue in 2016 and the trend is projected to grow throughout the forecast period. Pemetrexed and combination segment is also the most attractive segment, recording a market attractiveness index of 3.2 over the forecast period.
Increased focus to obtain approvals for efficient combination therapy procedures is one of the significant factors driving revenue growth of the Pemetrexed and combination drug type segment
Most of the companies in the global malignant mesothelioma market are focusing on collaborating with organizations to study the combination of several drugs on malignant mesothelioma. As there are very few companies that have patents for procedures, many companies are conducting clinical trials focusing on different combination drugs. For instance, in 2017, Boehringer Ingelheim entered into phase 3 for its double-blind, randomized, phase 3 study of Nintedanib in combination with Pemetrexed / Cisplatin followed by continuing Nintedanib monotherapy versus placebo in combination with Pemetrexed / Cisplatin followed by continuing placebo monotherapy for mesothelioma treatment. All these efforts by the key players in the market are boosting the growth of the Pemetrexed and combination segment.
It is assumed that asbestos exposure leads to malignant mesothelioma and given the restrictions on asbestos use globally, it is expected that cases of mesothelioma will reduce in the near future. However, the number of malignant mesothelioma cases do not support these assumptions. As per statistics released by the Cancer Research UK, 1 in every 140 men and 1 in every 710 women are diagnosed with malignant mesothelioma. It has been observed that there is an increasing trend of malignant mesothelioma cases in men. This particular factor is fuelling the growth in revenue of the Pemetrexed and combination segment.
Evaluation of combination therapies over monotherapy is one of the main factors creating a positive impact on the Pemetrexed and combination drug type segment. Combination therapies such as those using chemotherapy with radio, targeted antibody, cryotherapy, or with other immunotherapies are likely to expand the potential indications for various drugs. These combination therapies also seek to improve survival rates considerably, as has been evident from limited clinical data in comparison with only surgeries or radiation therapies. Various companies have identified that multiple pathways are affected in tumor regulation and hence seek to use combination therapy as a more effective method.
The highest CAGR of the Pemetrexed and combination drug type segment is likely to be recorded in the APEJ malignant mesothelioma market
Pemetrexed and combination drug type segment stands the most attractive in the Latin America malignant mesothelioma market, representing a market attractiveness index of 2.7. In the APAC and MEA regional markets, the segment is expected to reach the highest CAGR of 9.5% and 7.5% respectively during the period of forecast.